EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
European Organisation for Research and Treatment of Cancer · Fondazione Ricerca Molinette · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
633
total citations
- FWCI
- 33.40
- Percentile
- 100%
- References
- 23
Citations per year
Authors
16- SCSamantha Cambier
European Organisation for Research and Treatment of Cancer
- RSRichard SylvesterCorresponding
European Organisation for Research and Treatment of Cancer
- LCLaurence Collette
European Organisation for Research and Treatment of Cancer
- PGPaolo Gontero
Fondazione Ricerca Molinette
- MBMaurizio Brausi
Topics & keywords
Topics
Keywords
- Medicine
- Nomogram
- Bladder cancer
- Cystectomy
- Carcinoma in situ
- Stage (stratigraphy)
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.